(PLSE) Pulse Biosciences - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 1.792m USD | Total Return: 53.6% in 12m
Avg Turnover: 6.59M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Interest Coverage Ratio -4.2 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Choppy
Tailwinds
Rs Leader, Idiosyncratic Leader, Tailwind, Pullback 52w
Pulse Biosciences, Inc. is a medical technology company specializing in Nanosecond Pulsed-Field Ablation (nsPFA). The firm develops the CellRescale and nPulse platforms, which utilize ultra-short energy pulses to target cellular structures without damaging surrounding non-cellular tissue. Its product pipeline addresses clinical needs in dermatology, soft tissue surgery, and cardiac electrophysiology, specifically targeting atrial fibrillation.
The company operates within the bioelectric medicine sector, a field focused on using electrical signaling to treat chronic conditions as an alternative to traditional pharmacology or thermal ablation. This business model relies heavily on a razor-and-blade strategy, where the sale of software-enabled consoles drives recurring revenue through the disposal of procedure-specific electrodes and catheters.
You can find further data regarding the companys valuation and market position at ValueRay. Pulse Biosciences is headquartered in Miami, Florida, and has transitioned from its original identity as Electroblate, Inc. to focus exclusively on its proprietary pulse-power technology.
- FDA regulatory clearance timelines for cardiac surgical clamp and catheter systems
- Clinical trial data outcomes for nanosecond pulsed-field ablation in atrial fibrillation
- Commercial adoption rates of nPulse console across hospital surgical departments
- Capital requirements and potential share dilution to fund ongoing clinical development
- Strategic partnership announcements with established medical device distributors and healthcare providers
| Net Income: -74.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.68 > 0.02 and ΔFCF/TA -37.82 > 1.0 |
| NWC/Revenue: 8.17k% < 20% (prev 4.53k%; Δ 3.63k% < -1%) |
| CFO/TA -0.68 > 3% & CFO -55.2m > Net Income -74.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (67.8m) vs 12m ago 0.99% < -2% |
| Gross Margin: -91.08% > 18% (prev 0.34%; Δ -9.14k% > 0.5%) |
| Asset Turnover: 0.70% > 50% (prev 1.87%; Δ -1.17% > 0%) |
| Interest Coverage Ratio: -4.20 > 6 (EBITDA TTM -77.0m / Interest Expense TTM 18.6m) |
| A: 0.75 (Total Current Assets 71.1m - Total Current Liabilities 9.80m) / Total Assets 81.6m |
| B: -5.90 (Retained Earnings -481.9m / Total Assets 81.6m) |
| C: -0.73 (EBIT TTM -78.0m / Avg Total Assets 107.5m) |
| D: -31.44 (Book Value of Equity -481.8m / Total Liabilities 15.3m) |
| Altman-Z'' = -52.21 = D |
As of May 27, 2026, the stock is trading at USD 26.00 with a total of 182,665 shares traded.
Over the past week, the price has changed by +1.52%,
over one month by +14.79%,
over three months by +34.78% and
over the past year by +53.57%.
Pulse Biosciences has no consensus analysts rating.
| Analysts Target Price | 30 | 15.4% |
P/S = 2385.938
P/B = 26.954
Revenue TTM = 751k USD
EBIT TTM = -78.0m USD
EBITDA TTM = -77.0m USD
Long Term Debt = 5.53m USD (estimated: total debt 7.16m - short term 1.63m)
Short Term Debt = 1.63m USD (from shortTermDebt, last quarter)
Debt = 7.16m USD (from shortLongTermDebtTotal, last quarter) (leases 7.16m already included)
Net Debt = -61.2m USD (calculated: Debt 7.16m - CCE 68.3m)
Enterprise Value = 1.73b USD (1.79b + Debt 7.16m - CCE 68.3m)
Interest Coverage Ratio = -4.20 (Ebit TTM -78.0m / Interest Expense TTM 18.6m)
EV/FCF = -31.18x (Enterprise Value 1.73b / FCF TTM -55.5m)
FCF Yield = -3.21% (FCF TTM -55.5m / Enterprise Value 1.73b)
FCF Margin = -7.39k% (FCF TTM -55.5m / Revenue TTM 751k)
Net Margin = -9.93k% (Net Income TTM -74.6m / Revenue TTM 751k)
Gross Margin = -91.08% ((Revenue TTM 751k - Cost of Revenue TTM 1.44m) / Revenue TTM)
Gross Margin QoQ = 7.73% (prev -96.59%)
Tobins Q-Ratio = 21.20 (Enterprise Value 1.73b / Total Assets 81.6m)
Interest Expense / Debt = 259.7% (Interest Expense 18.6m / Debt 7.16m)
Taxrate = 21.0% (US default 21%)
NOPAT = -61.7m (EBIT -78.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.26 (Total Current Assets 71.1m / Total Current Liabilities 9.80m)
Debt / Equity = 0.11 (Debt 7.16m / totalStockholderEquity, last quarter 66.3m)
Debt / EBITDA = 0.79 (negative EBITDA) (Net Debt -61.2m / EBITDA -77.0m)
Debt / FCF = 1.10 (negative FCF - burning cash) (Net Debt -61.2m / FCF TTM -55.5m)
Total Stockholder Equity = 86.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -69.36% (Net Income -74.6m / Total Assets 81.6m)
RoE = -13.13% (Net Income TTM -74.6m / Total Stockholder Equity 567.9m)
RoCE = -13.61% (EBIT -78.0m / Capital Employed (Equity 567.9m + L.T.Debt 5.53m))
RoIC = -159.7% (out of range, set to none) (NOPAT -61.7m / Invested Capital 38.6m)
WACC = 9.73% (E(1.79b)/V(1.80b) * Re(9.77%) + (debt cost/tax rate unavailable))
Discount Rate = 9.77% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 9.69%
[DCF] Fair Price = unknown (Cash Flow -55.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.50 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.00 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.24 | Chg30d=-4.35% | Revisions=-20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.24 | Chg30d=-9.09% | Revisions=-20% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.91 | Chg30d=-7.06% | Revisions=-20% | GrowthEPS=-20.6% | GrowthRev=+800.0%
EPS next Year (2027-12-31): EPS=-0.88 | Chg30d=-2.33% | Revisions=-20% | GrowthEPS=+3.3% | GrowthRev=+296.8%